Skip to main content

Compounded medication
Dispensed by a licensed 503A compounding pharmacy
Prescribed only when clinically appropriate

Oral tirzepatide tablet bottle503A · CompoundedIllustration only. Actual medication will vary.

Weight Management · Needle-free dual agonist

Oral
Tirzepatide

One dissolvable tablet per day. Tirzepatide paired with low-dose ondansetron for nausea support, a needle-free option for dual-pathway metabolic care.

503A · CompoundedPhysician-reviewedU.S. pharmacy

Your Plan Options

3 mg

Tirzepatide 3 mg / Ondansetron 2 mg ODT · 30 tabs/mo · 30-day supply

$299 /mo

3 mg

Tirzepatide 3 mg / Ondansetron 2 mg ODT · 30 tabs/mo · 90-day supply

$799 /3 mo

Best value

4 mg

Tirzepatide 4 mg / Ondansetron 2 mg ODT · 30 tabs/mo · 30-day supply

$319 /mo

4 mg

Tirzepatide 4 mg / Ondansetron 2 mg ODT · 30 tabs/mo · 90-day supply

$879 /3 mo

Best value

5 mg

Tirzepatide 5 mg / Ondansetron 2 mg ODT · 30 tabs/mo · 30-day supply

$349 /mo

5 mg

Tirzepatide 5 mg / Ondansetron 2 mg ODT · 30 tabs/mo · 90-day supply

$939 /3 mo

Best value

6 mg

Tirzepatide 6 mg / Ondansetron 2 mg ODT · 30 tabs/mo · 30-day supply

$379 /mo

6 mg

Tirzepatide 6 mg / Ondansetron 2 mg ODT · 30 tabs/mo · 90-day supply

$1,029 /3 mo

Best value

Begin your consultation

No charge until a provider prescribes. Prescription required.

Clinical information

What this is, in plain language.

Oral tirzepatide ODT combines tirzepatide, a dual GIP/GLP-1 receptor agonist, with 2 mg of ondansetron in one orally disintegrating tablet taken daily. It is prepared by a licensed 503A compounding pharmacy and dispensed only when a licensed provider determines it is clinically appropriate.

Active ingredients

Tirzepatide (3, 4, 5 or 6 mg) and ondansetron 2 mg.

Mechanism

Dual GIP/GLP-1 receptor agonist, with ondansetron to help manage nausea.

Administration

One orally disintegrating tablet daily. Strength adjusted under clinical guidance.

Who it is for

Adults evaluating needle-free dual-pathway metabolic care, when clinically appropriate.

Common effects

Nausea, reduced appetite, constipation, headache. Discuss full risks with your provider.

Important safety & compliance information

Compounded tirzepatide / ondansetron ODT is not FDA-approved. It is prepared by a licensed 503A compounding pharmacy and is descriptive only — it is not a branded drug. Product imagery shown here is illustration only; actual medication is dispensed in a pharmacy-labeled container and will vary in appearance. A prescription is required and is issued only when a licensed provider determines treatment is clinically appropriate. This page is not medical advice. Discuss benefits, risks and side effects with your provider.